194.19
price down icon0.08%   -0.16
after-market After Hours: 194.19
loading
Abbvie Inc stock is traded at $194.19, with a volume of 2.84M. It is down -0.08% in the last 24 hours and down -0.21% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$194.35
Open:
$195
24h Volume:
2.84M
Relative Volume:
0.65
Market Cap:
$343.01B
Revenue:
$55.00B
Net Income/Loss:
$5.34B
P/E Ratio:
53.20
EPS:
3.65
Net Cash Flow:
$17.78B
1W Performance:
-0.05%
1M Performance:
-0.21%
6M Performance:
+15.92%
1Y Performance:
+30.03%
1-Day Range:
Value
$193.58
$195.24
1-Week Range:
Value
$191.95
$195.24
52-Week Range:
Value
$135.85
$199.95

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
50,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
07:31 AM

Simplicity Wealth LLC Reduces Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat

07:31 AM
pulisher
05:40 AM

There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors. - The Motley Fool

05:40 AM
pulisher
Oct 11, 2024

AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch

Oct 11, 2024
pulisher
Oct 11, 2024

AbbVie (NYSE:ABBV) Trading Up 0.1% on Analyst Upgrade - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Ex-Dividend Reminder: Hormel Foods, Abbott Laboratories and AbbVie - Nasdaq

Oct 11, 2024
pulisher
Oct 11, 2024

Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and more - Seeking Alpha

Oct 11, 2024
pulisher
Oct 11, 2024

CCM Investment Advisers LLC Sells 6,991 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Is AbbVie Inc. (NYSE:ABBV) The Most Popular Stock Among Mutual Funds According To Goldman Sachs? - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

AbbVie (ABBV) Stock Moves -0.21%: What You Should Know - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 10, 2024
pulisher
Oct 10, 2024

AbbVie (NYSE:ABBV) Shares Down 0.3%What's Next? - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

AbbVie Shares Rebound After Six-day Slump Despite Ongoing Challe - GuruFocus.com

Oct 10, 2024
pulisher
Oct 10, 2024

AbbVie Shares Rebound After Six-day Slump Despite Ongoing Challenges - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

Autoimmune Hepatitis Market to Rise, 2032 | AbbVie Inc., Gilead - openPR

Oct 10, 2024
pulisher
Oct 10, 2024

Design Firm Helps Drugmaker Improve Ergonomics of Injector Pen - Assembly Magazine

Oct 10, 2024
pulisher
Oct 10, 2024

AbbVie (NYSE:ABBV) Given New $215.00 Price Target at Truist Financial - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Abbvie pulls 2 hepatitis treatments from EU market - Liver Disease News

Oct 10, 2024
pulisher
Oct 10, 2024

Tobam Lowers Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Geriatric Medicine Industry Assessment 2024-2030, Featuring - GlobeNewswire

Oct 10, 2024
pulisher
Oct 10, 2024

AbbVie 2024: What’s next - PharmaLive

Oct 10, 2024
pulisher
Oct 10, 2024

GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News

Oct 10, 2024
pulisher
Oct 09, 2024

UBS Group Increases AbbVie (NYSE:ABBV) Price Target to $195.00 - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 09, 2024
pulisher
Oct 09, 2024

AbbVie snaps six days of losses, trades in the green - Seeking Alpha

Oct 09, 2024
pulisher
Oct 09, 2024

Tia Mowry gets real about eczema at AbbVie’s NYC pop-up - MM+M Online

Oct 09, 2024
pulisher
Oct 09, 2024

AbbVie (NYSE:ABBV) Shares Down 0.2%What's Next? - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

AbbVie Inc. (NYSE:ABBV) Shares Purchased by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Germany Pharmaceuticals Market Report 2024-2028: Consolidation through Mergers and Acquisitions Catalyzing Growth - GlobeNewswire Inc.

Oct 09, 2024
pulisher
Oct 08, 2024

AbbVie Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 08, 2024
pulisher
Oct 08, 2024

AbbVie (NYSE:ABBV) Stock Price Down 0.5%Time to Sell? - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Legacy Private Trust Co. Grows Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

AbbVie's Top Brass Escape Suit Over Rinvoq Claims, For Now - Law360

Oct 07, 2024
pulisher
Oct 07, 2024

AbbVie (NYSE:ABBV) Trading 0.4% Higher After Analyst Upgrade - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

AbbVie (NYSE:ABBV) Price Target Raised to $212.00 at Barclays - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

AbbVie Investors’ Suit Over Rinvoq Marketing Risks Dismissed - Bloomberg Law

Oct 07, 2024
pulisher
Oct 07, 2024

AbbVie Inc. (NYSE:ABBV) is Oak Asset Management LLC's 7th Largest Position - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades' - MSN

Oct 07, 2024
pulisher
Oct 07, 2024

Breast tumors may mimic neurons to invade the brain - Drug Discovery News

Oct 07, 2024
pulisher
Oct 06, 2024

3 Magnificent Dividend Stocks to Buy in October - The Motley Fool

Oct 06, 2024
pulisher
Oct 06, 2024

Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You? - The Motley Fool

Oct 06, 2024
pulisher
Oct 05, 2024

Handelsbanken Fonder AB Has $226.30 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat

Oct 05, 2024
pulisher
Oct 05, 2024

2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now - The Motley Fool

Oct 05, 2024
pulisher
Oct 05, 2024

Ausdal Financial Partners Inc. Sells 456 Shares of AbbVie Inc. (NYSE:ABBV) - Defense World

Oct 05, 2024
pulisher
Oct 04, 2024

EU withdraws marketing authorisation for Abbvie's hepatitis C drug - AOL

Oct 04, 2024
pulisher
Oct 04, 2024

AbbVie (NYSE:ABBV) Trading Down 0.7%Should You Sell? - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

AbbVie trims full-year earnings guidance due to R&D milestone costs - PharmaLive

Oct 04, 2024
pulisher
Oct 04, 2024

AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs - Yahoo Finance

Oct 04, 2024
pulisher
Oct 04, 2024

Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM - AbbVie

Oct 04, 2024

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$161.46
price up icon 0.59%
drug_manufacturers_general MRK
$109.73
price up icon 0.30%
drug_manufacturers_general NVS
$116.22
price up icon 1.23%
$328.35
price up icon 2.29%
drug_manufacturers_general PFE
$29.16
price down icon 0.61%
Cap:     |  Volume (24h):